The Patent Finder

Glycomimetics, Inc.

Also on record
Records under this name other than the patents Glycomimetics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 24 patents it holds.

Back to Glycomimetics, Inc.

PatentTitleStatus Expires Confidence
US 8,518,896Treatment of cancers of the blood using selected glycomimetic compounds
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,291,678Methods for the Treatment And/Or Prevention of Cardiovascular Disease by Inhibition of E-Selectin
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,433,086Combination of T-Cell Checkpoint Inhibitors with Inhibitors of E-Selectin or CXCR4, or with Heterobifunctional Inhibitors of Both E-Selectin and CXCR4
Lapsed on the fee record
Ended Sep 6, 2026 · High confidence
Lapsed on the fee recordEnded Sep 6, 2026High confidence
US 7,989,601Heterobifunctional pan-selectin inhibitors
Term ended
Term ended Sep 1, 2026 · From the USPTO record
Term endedTerm ended Sep 1, 2026From the USPTO record
US 7,361,644Specific antagonist for both E- and P-selectins
Term ended
Term ended Apr 14, 2026 · From the USPTO record
Term endedTerm ended Apr 14, 2026From the USPTO record
US 8,633,303Heterobifunctional pan-selectin inhibitors
Lapsed on the fee record
Ended Jan 21, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jan 21, 2026From the USPTO record
US 11,197,877Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
Lapsed on the fee record
Ended Dec 14, 2025 · From the USPTO record
Lapsed on the fee recordEnded Dec 14, 2025From the USPTO record
US 9,796,745E-selectin antagonist compounds, compositions, and methods of use
Lapsed on the fee record
Ended Oct 24, 2025 · From the USPTO record
Lapsed on the fee recordEnded Oct 24, 2025From the USPTO record
US 11,045,485Glycomimetic inhibitors of PA-IL and PA-IIL lectins
Lapsed on the fee record
Ended Jun 29, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jun 29, 2025From the USPTO record
US 8,410,066Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
Lapsed on the fee record
Ended Apr 2, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 2, 2025From the USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited